Milestone Pharmaceuticals reported positive early sales for CARDAMYST and secured Express Scripts coverage, which is expected to enhance patient access. The Phase 3 trial for atrial fibrillation will begin enrolling patients in late 2026, while the company maintains a robust cash position to support growth through 2027. Overall, these developments highlight the potential for increased market penetration and subsequent revenue growth.
Milestone Pharmaceuticals (NASDAQ:MIST) is scheduled to release its fourth-quarter earnings on March 20, with analysts projecting a loss of 16 cents per share. The anticipated revenue of $1.20 million may impact market perceptions, especially as it follows a leadership change with the recent appointment of David Sandoval as general counsel.
